Les maladies chroniques non transmissibles (MCNT) constituent un problème de santé publique. La transition épidémiologique coexiste avec les maladies infectieuses. En Afrique subsaharienne, leur ampleur est peu connue et l'OMS recommande aux pays à faible et moyen revenu de réaliser des enquê...tes STEPS portant sur les comportements, des mesures physiques et biochimiques. L'absence de données au niveau national justifie cette étude auprès d'un groupe spécifique. L'objectif de l'étude était de déterminer la prévalence des MCNT et de leurs facteurs de risque chez les militaires Sénégalais.
more
Connecting global priorities: biodiversity and human health: a state of knowledge review
DHS Further Analysis Reports No. 97
Who suffers Most from Extreme Weather Events? Weather-related Loss Events in 2019 and 2000 to 2019
The Global Climate Risk Index 2021 analyses and ranks to what extent countries and regions have been affected by impacts of climate related extreme weather events (storms, floods, heatwaves etc.). The... most recent data available for 2019 and from 2000 to 2019 was taken into account.
more
Morbidity and Mortality Weekly Report (MMWR) January 16, 2015 / 64(01);20-27
The Minimum Standards for Age and Disability Inclusion in Humanitarian Action inform the design, implementation, monitoring and evaluation of humanitarian programmes across all sectors and phases of response, and in all emergency contexts, ensuring older people and people with disabilities are not e...xcluded.
more
Training Modules for climate change and Health - WHO
This Technical Brief focuses on current principles and approaches to Moderate Acute Malnutrition (MAM) management, highlighting key constraints, gaps in knowledge and areas still lacking consensus. It is intended to inform ongoing debates among practitioners, national partners, donors and analysts o...n what information and evidence on best practices are currently available, where the gaps are, and priorities for going forward.
more
Including a Tool to Assess the Adolescent Health and Development Component in Pre-Service Education of Health-Care Providers
With this World Health Day, WHO is drawing attention to a group of diseases that are spread by insects and other vectors, the heavy health and economic burdens they impose, and what needs to be done to reduce these burdens. Many of these diseases have been historically confined to distinct geographi...cal areas, but this situation has become more fluid due to a host of ills, including climate change, intensive farming, dams, irrigation, deforestation, population movements, rapid unplanned urbanization, and phenomenal increases in international travel and trade. The control of vector-borne diseases can make a major contribution to poverty reduction, as it precisely targets the poor
more
This handbook reflects and updates the work that ECLAC has done in recent decades to establish a methodology for estimating the economic consequences of a disaster, and thus determine the financing required to rebuild and return the affected area to normal. The handbook's third edition strengthens p...rocedures for estimating the effects of disasters, for distinguishing between losses and additional costs and systematizing the links that exist between different sectors of the economy
more
The Compendium brings together for the first time key consensus-based policy recommendations and guidance to improve the delivery of proven interventions to women and children. The user-friendly format incorporates icons and tabs to present key health-related policies that support the delivery of es...sential RMNCH interventions. It also includes multisectoral policies on the economic, social, technological and environmental factors that influence health outcomes and service delivery. The Policy Compendium is a companion document to the Essential Interventions, Commodities and Guidelines for RMNCH.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more